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Abstract
Vasoactive intestinal peptide (VIP) is a pleiotropic neuropeptide with immunomodulatory properties. The administration of
this peptide has been shown to have beneficial effects in murine models of inflammatory diseases including septic shock,
rheumatoid arthritis, multiple sclerosis (MS) and Crohn’s disease. However, the role of the endogenous peptide in
inflammatory disease remains obscure because VIP-deficient mice were recently found to exhibit profound resistance in a
model of MS. In the present study, we analyzed the response of female VIP deficient (KO) mice to intraperitoneal
lipopolysaccharide (LPS) administration. We observed significant resistance to LPS in VIP KO mice, as evidenced by lower
mortality and reduced tissue damage. The increased survival was associated with decreased levels of proinflammatory
cytokines (TNFa, IL-6 and IL-12) in sera and peritoneal suspensions of these mice. Moreover, the expression of TNFa and IL-6
mRNA was reduced in peritoneal cells, spleens and lungs from LPS-treated VIP KO vs. WT mice, suggesting that the
resistance might be mediated by an intrinsic defect in the responsiveness of immune cells to endotoxin. In agreement with
this hypothesis, peritoneal cells isolated from VIP KO naive mice produced lower levels of proinflammatory cytokines in
response to LPS in vitro. Finally, decreased NF-kB pathway activity in peritoneal cells was observed both in vivo and in vitro,
as determined by assay of phosphorylated I-kB. The results demonstrate that female VIP KO mice exhibit resistance to LPS-
induced shock, explainable in part by the presence of an intrinsic defect in the responsiveness of inflammatory cells to
endotoxin.
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Introduction
Inflammation is an essential mechanism of self-protection
against pathogen invasion and injury, and involves innate and
adaptive immune mechanisms [1]. Macrophages, critical effector
cells of the innate immune response, play a major role in this
process by releasing pro-inflammatory cytokines such as tumor
necrosis factor (TNF)-a, interleukin (IL)-1b, IL-6 and IL-12, and
chemokines such as monocyte chemotactic protein (MCP)-1 or
macrophage inflammatory protein (MIP)-1a that promote leuko-
cyte recruitment to the damaged tissues [2]. In turn, the main
cellular effectors of innate immunity, macrophages and neutro-
phils, engulf and digest bacteria, remove cell debris, and produce
growth factors to facilitate the healing process [2,3,4]. However,
the ability of the immune system to mediate direct or indirect
killing of cells and pathogens make it a potential threat to host
survival. As a consequence, autoimmunity and acute and chronic
inflammatory diseases are triggered by immune dysfunction. In
this regard, septic shock is a serious acute inflammatory condition
often caused by an overwhelming infection that usually leads to
impaired perfusion and multiple organ failure [5]. The most
frequent microbial agents responsible for septicemia are Gram-
negative bacteria. In addition to the release of bacterial toxins,
lipopolysaccharide (LPS), a major component of Gram negative
bacteria outer membranes, binds preferentially to toll-like receptor
(TLR)-4 expressed by many immune and non-immune cell types
[6]. This triggers the activation of the nuclear factor kappa B (NF-
kB) pathway, which causes the release of inflammatory mediators
[7,8]. Pathology arises when the presence of excessive levels of
endotoxin due to bacterial overgrowth leads to a hyperactivation
of macrophages and granulocytes that massively invade all tissues
and release proinflammatory mediators. This phenomenon can be
experimentally mimicked in animals by administration of an
exogenous high dose of LPS.
Although proper control of the immune response is not always
achievable, the organism has developed different endogenous
mechanisms to control the inflammatory response and preserve
homeostasis [9]. These include the production of soluble mediators
such as the anti-inflammatory cytokine IL-10, heat shock proteins,
certain prostaglandins, and hormones such as cortisol. Lately,
several neuropeptides have been suggested to be immune
modulators that dampen the inflammatory response, including
the structurally-related peptides VIP and PACAP (vasoactive
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17intestinal peptide and pituitary adenylate cyclase-activating
polypeptide, respectively) [10]. These natural inhibitors of
immunity are currently being tested as potential therapeutic
candidates for the treatment of inflammatory diseases.
VIP is a versatile 28-amino acid neuropeptide with thoroughly
described anti-inflammatory functions [11,12]. VIP binds mainly
to two receptors, named VPAC1 and VPAC2, which belong to the
G-coupled protein receptor family and are expressed on many
different immune cell types [13]. Numerous in vitro and in vivo
studies have demonstrated that VIP, via actions on these receptors,
is able to suppress the production and/or release of key molecules
for the inflammatory response, such as proinflammatory cytokines,
and chemokines [14,15]. In fact, the potential use of VIP as a
treatment for acute and chronic inflammatory diseases including
septic shock, rheumatoid arthritis, Crohn’s disease and multiple
sclerosis has been suggested based on positive clinical and
pathological outcomes in corresponding murine models of
inflammatory diseases [16,17,18,19]. In addition, it has been
demonstrated that the systemic endogenous levels of this
neuropeptide increase in response to an inflammatory challenge
like endotoxic shock in humans or LPS-induced endotoxemia in
mice [20,21]. As VIP has been reported to be produced by
neurons, endocrine and immune cells, multiple tissular and
cellular sources can contribute to the increase of VIP after
inflammation. For example, it has been recently shown that LPS
induces the production of VIP by chromaffin cells from the
adrenal medulla [22]. In addition, VIP levels are upregulated in
cell suspensions from primary and secondary lymphoid organs in
response to LPS treatment [23]. Whether or not this upregulation
has an impact on the course of the inflammatory response is
largely unknown. VIP-deficient mice (KO) display certain
physiological abnormalities such as disrupted circadian rhythms,
airway hyperresponsiveness to the cholinergic agonist methacho-
line, and pulmonary hypertension [24,25,26]. In addition, we have
recently reported that despite the well-described anti-inflammato-
ry actions of VIP, VIP KO female mice were unexpectedly
resistant to experimental autoimmune encephalomyelitis (EAE)
induction, with reduced immune cell infiltration of the spinal cord
and brain parenchyma [27]. Potential mechanisms for this
resistance may include defects in the innate arm of immunity.
As a model to test this hypothesis, we investigated the response of
VIP KO mice to LPS-induced endotoxemia. We found that
female VIP KO mice exhibited reduced mortality in response to
LPS. This phenotype was associated with reduced inflammatory
damage in the lungs of the KO mice, and reduced levels of
proinflammatory mediators in the sera and peritoneal suspensions.
Moreover, we found reduced mRNA expression of TNFa and IL-
6 in peritoneal cells, spleens and lungs of LPS-treated VIP KO
mice. Interestingly, peritoneal cells isolated from naive VIP KO
mice produced lower levels of proinflammatory cytokines than
wild type [2] cells in response to LPS. Finally, NF-kB activation by
LPS was reduced in cells from VIP KO mice.
Materials and Methods
Mice
All animal studies were approved by the institutional animal
research committee of the University of California at Los Angeles
(UCLA) Female 6- to 8-week-old mice WT and VIP KO mice on
a C57BL/6 background (backcrossed for at least twelve genera-
tions) [25] were maintained under specific pathogen-free condi-
tions. Experimental procedures followed the recommendations for
animal use and welfare, as dictated by the UCLA Division of
Laboratory Animals and the guidelines from the National
Institutes of Health.
Induction of endotoxemia and histology
Endotoxemia was induced in mice by intraperitoneal (i.p.)
injection of 40 mg/Kg of LPS (Salmonella enteritidis; Sigma, St.
Louis, MO), and survival was monitored thereafter for at least one
week. For histopathological studies, separate cohorts of mice were
sacrificed 24 hours later and lungs were removed and fixed in
Bouin’s solution for 2 hours. Fixed tissues were then dehydrated
and embedded in paraffin, sectioned, and stained with hematox-
ylin and eosin for morphological examination. The degree of
inflammation was scored from 0 to 3 by two independent
researchers in a blinded fashion as described [28]: 0 - all alveolar
septae thin and delicate, no hemorrhage or fibrosis present; 1 -
congested alveolar septae in less than 1/3 of the field, mild
hemorrhage and fibrosis in less than 1/3 of the field; 2- congested
alveolar septae 1/3 to 2/3 of the field, moderate hemorrhage and
fibrosis in 1/3 to 2/3 of the field, 3: congested alveolar septae in
more than 2/3 of the field, severe hemorrhage and fibrosis in more
than 2/3 of the field.
Collection of sera and peritoneal supernatants
For cytokine measurements, mice were sacrificed 3 and 6 hours
after LPS injection (or 3, 6 and 24 hours for IL-10), blood was
collected by intracardiac puncture under anesthesia, and serum
was obtained after clotting for 2 hours at room temperature. In
order to collect peritoneal suspensions at these time points, mice
were injected i.p. with 2 ml of RPMI 1640 (Gibco, Gaithersburg,
MD) and fluid was collected after abdominal massage. In both
cases, samples were centrifuged for 10 min at 2000 rpm and
supernatants were stored at 220uC until assay.
RNA isolation and Real time-PCR analysis
RNA was extracted from cells from peritoneal suspension
collected as above, and from spleens and lungs at the indicated
time points with Trizol (Invitrogen, Carlsbad, CA) as recom-
mended by the manufacturer. RNA was resuspended in
diethylpyrocarbonate (DEPC) water and quantified at 260/
280 nm. cDNA from 1 mg of RNA was synthesized with the
iScriptTM cDNA synthesis Kit from Bio-Rad (Hercules, CA).
Quantitative real-time PCR analysis was performed using the
iQ
TM SYBR Green Supermix from Bio-Rad in triplicate in 25 ml
reaction volumes. The sequences of the primers used were: mouse
HPRT 59-TGGTGAAAAGGACCTCTCGAA-OH sense and 59-
TCAAGGGCATATCCAACAACA-OH antisense, mouse TNFa
sense 59-CGATCACCCCGAAGTTCAGTA-OH and 59-
GGTGCCTATGTCTCAGCCTCTT-OH antisense, mouse IL-
65 9-TTCCATCCAGTTGCCTTCTTG–OH sense and 59-
TTGGGAGTGGTATCCTCTGTGA–OH antisense. The Gen-
Bank accession numbers for the PCR products are: HPRT,
NM013556; TNFa, NM013693; IL-6, NM031168. The amplifi-
cation conditions were 4 min at 95uC followed by 40 cycles of
denaturation at 96uC for 20 sec, annealing at (60uC for IL-6, 62uC
for TNFa), for 30 sec and extension at 72uC for 30 sec. The
specificity of gene amplification was confirmed by sequencing of
the PCR products and melting curves analysis. Comparison of
specific ratios (gene of interest/house keeping gene) was used to
assess differences between groups.
In vitro studies
For cell culture studies, peritoneal lavage was obtained as
described above. Whole peritoneal cells were washed and cultured
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5 cells/well in 200 ml/well
with RPMI 1640 complete medium (2% FCS, 2 mM L-glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin) and 10 ng/ml
of LPS (Salmonella enteritidis; Sigma) at 37uC in a 5% CO2
humidified atmosphere. Supernatants were collected at different
time points, centrifuged at 2000 rpm and stored at 220uC until
assay of cytokines by ELISA.
ELISA
TNFa, IL-6, IL-10 and IL-12p40 quantities in serum,
peritoneal suspension or culture supernatants were determined
by standard sandwich ELISA. Development kits were used
according to manufacturer instructions (Peprotech, Rocky Hill,
NJ). Briefly, 96 well plates (Corning, NY) were coated with capture
antibody O/N at room temperature. After blocking for 1 hour
with PBS/1%BSA, samples and standards were added O/N at
4uC. Plates were then incubated with detection antibody for
2 hours, and avidin/peroxidase was added for 30 min. Washing
four times with PBS/0.05%Tween was performed before the
addition of all reagents. Finally, plates were incubated with
substrate solution and A405 nm was measured 30 minutes later with
a Bio-Rad microplate reader.
Western blot
For analysis of freshly isolated peritoneal cells (in vivo), mice were
injected with LPS and cells were collected one hour later from
peritoneal lavage. For in vitro studies, peritoneal cells were
incubated with 10 ng/ml of LPS as above and collected 15 min
later. In both cases cells were centrifuged and pellets were frozen
in dry ice. Pelletted cells were homogenized in RIPA buffer
containing protease inhibitor cocktail (Roche, Indianapolis, IN)
and phosphatase inhibitor cocktail (Sigma). Concentration of total
protein was determined using a BCA kit (GE healthcare,
Piscataway, NJ) and 20 mg of protein was resolved on a 4–20%
gradient polyacrylamide gel (Invitrogen) and transferred to PVDF
membranes (Bio-Rad). Membranes were then incubated with
primary antibody for phosphorylated IkB (Santa Cruz, CA),
appropriate secondary antibody conjugated to horse-radish
peroxidase (Cell Signaling, Danvers, MA), and visualized using
ECL plus (GE healthcare). During the steps of blocking, primary
and secondary antibody incubations for p-IkB, the same
phosphatase inhibitor cocktail was added. Films were scanned,
and band density was quantified using digital image densitometry
analysis (ImageJ; National Institutes of Health, Bethesda, MD).
Statistical analysis
Graphs were created with the GraphPad 4.0 Prism software. All
results were expressed as means 6 SEM. Survival curves were
analyzed by Logrank (Mantel-Haenszel) test and ELISA, Real
time-PCR and Western blot data were analyzed by ANOVA and
Student t-test, with p,0.05 as the minimum level of significance.
Results
Increased survival of VIP KO vs WT mice after LPS
administration
We previously reported that female VIP KO mice exhibited a
paradoxical resistance to EAE induction [27]. To determine if the
resistance in these mice could potentially be explained by a defect
in innate immunity, we injected LPS (40 mg/kg) i.p. to female WT
and VIP KO mice and monitored their survival over time. The
administration of this endotoxin triggers an acute inflammatory
response leading to multiple organ dysfunction and subsequently
death in wild type mice within two to three days. Figure 1A depicts
the Kaplan-Meier analysis of WT vs. VIP KO survival of four
experiments. In the first 24 hours after LPS injection, WT and
VIP KO mice succumbed to LPS at a similar rate, with 50.0% and
58.6% survival for WT and VIP KO mice, respectively, and no
significant differences between the two curves. After this time
point, the mortality rates dramatically diverged, with few deaths
occurring in the VIP KO group in the next 24 hours, and none
after 48 hours post-injection. At the end of the study (5 days after
LPS administration), a significantly higher overall survival of VIP
KO mice (44.8%) vs WT mice (3.6%) was observed (**p=0.0049;
curve comparison Logrank test). For histopathological studies we
chose the lung, a main target tissue for immune cell infiltration and
inflammation in this model of LPS-induced endotoxemia. After
LPS administration, lung inflammatory injury is characterized by
patchy areas of neutrophilic infiltrates with thickening of the
alveolar septae. Interestingly, we found a mild degree of basal
inflammation in female VIP KO mice lungs (0.560.29 histological
score) compared to those of WT controls (Figure 1B), as it has
been previously reported in males [24]. However, in agreement
with our clinical data, whereas the lungs of WT mice exhibited
severe infiltration by immune cells 24 hours after LPS, those of the
VIP KO mice were significantly less inflamed and exhibited a
better preserved architecture (Figure 1B). Indeed, the average
histopathological score post-LPS administration was 2.2560.24
for WT mice, vs 1.5360.26 for VIP KO mice (*p,0.05)
(Figure 1C). Interestingly, we did not observe such a resistant
clinical phenotype to LPS in VIP KO male mice (data not shown),
suggesting that the effects of chronic absence of VIP could be sex
dependent. In this sense, sex differences in the composition of the
peritoneal cell population have been reported [29].
Proinflammatory cytokine levels are reduced in sera and
peritoneal suspensions of VIP KO mice after LPS
administration
LPS triggers the secretion of proinflammatory cytokines by a
wide array of cell types as a part of the innate immune response. In
order to determine if the ability of VIP KO mice to develop such a
response was impaired, we measured the protein levels of TNFa,
IL-6 and IL12p40 in the sera and the peritoneal suspensions of
LPS injected mice by ELISA. As shown in Figure 2, the levels of all
these cytokines increased in the serum and peritoneal fluid of the
WT mice in response to LPS as expected, with different time-
courses. For TNFa, there was an early induction with a peak only
3 hours after the injection of LPS in both types of samples (3-fold
increase compared to basal levels). For IL-6 and IL-12, the levels
increased progressively reaching the maximum 6 hours after the
induction of the disease (3-fold or higher fold increase over
controls). Supporting the clinical phenotype of VIP KO mice, even
though we found an increase of proinflammatory cytokines after
LPS injection in the sera and peritoneal suspensions of these mice,
the levels of these cytokines were lower than those in the WT mice.
The reduction in cytokine levels was particularly striking for TNFa
3 hours post-injection (0.4260.05 ng/ml in WT vs
0.2360.05 ng/ml in VIP KO mice; *p,0.05 in peritoneal
suspensions and 0.9860.09 ng/ml in WT vs 0.4160.08 ng/ml
in VIP KO mice; ***p,0.001 in sera). In addition, we measured
the levels of the antiinflammatory cytokine IL-10. As for the
proinflammatory cytokines analyzed, the levels of IL-10 were
lower in VIP KO mice than in WT mice at early time points,
especially 3 hours after LPS administration. Because IL-10 plays a
role in the resolution phase of inflammation, we also measured its
levels at a later time point, 24 hours post-LPS injection, which is
the time point after which the death rate decreased in the VIP KO
group. Interestingly, the levels of IL-10 in both peritoneal
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this time (***p,0.001). The findings that the KO mice produced
lower amounts of TNFa, IL-6, IL-12p40 and IL-10 at early time
points and produced more IL-10 at later time points suggest a
depressed response of the innate arm of immunity, and correlate
with the decreased mortality in the VIP KO mice.
VIP KO mice express lower levels of proinflammatory
mediators in peritoneal cells, spleen and lung
Peritoneal cells are the first immune cell population exposed to
LPS in this model. However, several studies have shown that LPS
rapidly access the circulation after intraperitoneal administration
and that its levels do not drop as quickly despite the clearing
activity of liver cells [30]. Therefore, circulating LPS triggers a
global inflammatory response whereby cells in different organs
such as the spleen and lung become activated and produce
proinflammatory mediators. These in turn promote immune cell
migration and tissue infiltration. Immigrant immune cells can in
turn amplify inflammation by producing more proinflammatory
cytokines. As shown above, the systemic levels of proinflammatory
cytokines were reduced in the VIP KO mice. In order to
investigate the source of this deficiency, we measured by real time
RT-PCR the mRNA levels of IL-6 and TNFa as representative
molecules of the inflammatory cascade, in peritoneal cells, spleen
and lung two hours after LPS injection. As expected (Figure 3A–
C), the mRNA levels of these two proinflammatory markers were
increased in all the WT mice tissues at 2 hours post-LPS injection.
However, the induction of these cytokines in VIP KO mice was
much less pronounced than in WT mice in all organs analyzed.
Only gene expression of IL-6 in the lung after LPS was not
different between WT and VIP KO mice. Interestingly, the
mRNA levels of TNFa in non-injected VIP KO lungs were higher
than in the WT mice, in agreement with the mild basal
inflammation found at the histological level in this organ in the
KO mice (**p,0.01). Our results suggest that in the chronic
absence of VIP, the LPS-induction of proinflammatory mediators
was impaired.
Peritoneal cells from VIP KO mice exhibit a reduced
cytokine response to LPS in vitro
In order to test whether the attenuated response to LPS in the
VIP KO mice was due to an intrinsic defect in the ability of
immune cells to mount an inflammatory response, we isolated and
cultured whole peritoneal cells from WT and VIP KO mice in the
presence or absence of LPS. Supernatants were collected to
measure the levels of TNFa and IL-6 by ELISA (Figure 4A, B).
We found that 2 hours after LPS stimulation, WT cells secreted
TNFa and IL-6 as expected (Figure 4A). In comparison, VIP KO
cells released lower cytokine levels (*p,0.05 for both cytokines).
To assess the possibility that cytokine release may be delayed in
VIP KO cells, we also collected the supernatants of similar cultures
16 hours after LPS stimulation (Figure 4B). Again, VIP KO cells
produced significantly lower amounts of TNFa and IL-6 at this
Figure 1. VIP KO mice exhibit reduced mortality and lung histopathology in response to LPS injection. Female WT (C57BL6) and VIP KO
mice were injected i.p. with LPS (40 mg/Kg). A, Kaplan Meier curve analysis of survival cumulative of four experiments (total WT n=29; VIP KO n=28)
(Curve comparison Logrank test **p,0.01). B, Representative sections of lungs from control (noninjected) or LPS-injected WT and VIP KO mice
(24 hours post injection) stained with H&E. C, Histological scores of LPS-injected WT vs. VIP KO mice (mean of two experiments; total WT n=7; VIP KO
n=9), 24 hours after LPS injection, scored from 0 to 3 according to the level of lung inflammation as described in Materials and Methods. (Student’s t-
test *p,0.05).
doi:10.1371/journal.pone.0036922.g001
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KO mice may present a defect in immune cells to respond to LPS.
NF-kB signaling is diminished in VIP KO peritoneal cells in
vivo and in vitro after LPS administration
The inflammatory cascade usually proceeds with the activation
of the NF-kB pathway, which leads to the synthesis of chemokines
and cytokines which amplify the immune response. In order to
identify potential defects leading to the resistance of VIP KO mice
to LPS, we studied the activity of this pathway in vitro and in vivo by
Western blot (Figure 5A, B). As a readout of NF-kB activation, we
studied the amount of phosphorylated-IkB (p-IkB) in protein
extracts from whole peritoneal cells isolated from WT and VIP
KO mice in basal conditions and 1 hour after LPS injection
(Figure 5A). Interestingly, the levels of p-IkB were already lower in
non-injected VIP KO mice compared to WT controls. The levels
of p-IkB increased in both WT and VIP KO mice post-LPS
injection. However, the levels of this signaling mediator after LPS
were significantly lower in VIP-deficient mice, suggesting a
reduced responsiveness of the NF-kB pathway in these mice. In
addition, we measured p-IkB in peritoneal cells cultured with and
without LPS as we did above for cytokine measurements
(Figure 5B). Similar to the results found in vivo, whereas LPS
treatment significantly elevated the levels of p-IkB in peritoneal
cells from WT mice (*p,0.05), it only triggered a modest increase
of p-IkB in cells from VIP KO mice (p=0.15). Indeed, the levels
of p-IkB in cells treated with LPS where lower in VIP KO mice
than in WT mice, although the difference was not significant
(p=0.08). The reduction of NF-kB signaling correlates with the
impaired secretion of proinflammatory cytokines in the VIP KO
mice.
Discussion
The antiinflammatory actions of VIP have been repeatedly
demonstrated both in vitro and in vivo, suggesting the therapeutic
potential of this peptide [11]. However, using the MOG35–55
immunization model, we recently reported that female VIP KO
mice exhibited an unexpected resistance to EAE induction [27],
suggesting that the activities of endogenous VIP in the immune
system may be complex. During the pathogenesis of EAE, both the
innate and adaptive arms of the immune system are involved [31].
Interestingly, we did not find a defect in the lymphocyte priming
phase in the VIP KO mice in our prior EAE study, because T cells
from immunized VIP KO mice showed robust responses to MOG
in vitro on antigen rechallenge experiments [27]. In addition, it has
been recently shown that VIP KO mice exhibited less weight loss
and improved survival to murine CMV infection, a phenotype
which was associated with enhanced adaptive antiviral cellular
immunity [32]. Thus, the activation of CD4 and CD8 T cells
following immunization does not appear to be impaired in these
mice. On the other hand, adoptive transfer of T cells from
MOG35–55-immunized WT mice induced EAE in WT but not
VIP KO mice [27], suggesting that impairments in one or more
cell types other than T cells might explain the EAE resistance in
the latter mice. Here, we used the LPS model of endotoxemia and
we found that VIP KO mice exhibited reduced mortality, less
tissue injury, and impaired proinflammatory responses. Because
the innate immune system is the major component in the
pathogenesis of this model, these results suggest that these mice
may exhibit a defect in this arm of immunity. We investigated
potential deficiencies in TNFa and IL-6 in these mice, as these are
two cytokines critically involved in the acute inflammatory
cascade. In this sense, TNFa is rapidly produced by immune cells
and is a major activator of the NF-kB pathway, which triggers the
Figure 2. VIP KO mice exhibit reduced levels of proinflammatory cytokines in the peritoneal fluid and serum. Female WT (C57BL6)
(n=6) and VIP KO mice (n=6) were injected i.p. with LPS (40 mg/Kg), and serum and peritoneal suspensions were collected 0, 3 and 6 (and also 24 for
IL-10) hours post-injection. The levels of TNFa, IL-6, IL-12p40 and IL-10 were assessed by sandwich ELISA as described in Material and Methods.
Student’s t-test *p,0.05; **p,0.01. One of three representative experiments is shown.
doi:10.1371/journal.pone.0036922.g002
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amplifying the immune response [33], IL-6, in addition to
generally being an inflammatory cytokine, activates the coagula-
tory cascade, and if present in excessively high levels, can lead to
disseminated intravascular coagulation, impaired reperfusion and
death [34]. In our study, we found a reduction in the systemic
levels of both TNFa and IL-6 in VIP KO mice injected with LPS.
Although multiple cell types can produce these cytokines, our
analysis of peritoneal cells infers that VIP KO mice may exhibit a
defect in immune cells, most likely within the myeloid component,
because the pool of peritoneal cells is highly represented by
myeloid cells including monocytes, macrophages and granulocytic
populations, and these cells are the main contributors to the rapid
increase in TNFa and IL-6 levels in response to LPS. It has been
shown that peritoneal cells play an important role in LPS-induced
endotoxemia. First of all, this is the initial immune cell population
exposed to the intraperitoneal LPS injection, and all cell
components express TLRs. Moreover, it has been shown that
peritoneal lavage performed before LPS administration to remove
these cells reduces the elevation of serum TNFa and IL-6 and
mortality in mice [35]. Here, we found decreased TNFa and IL-6
mRNA levels in peritoneal cells from VIP KO mice injected with
Figure 3. Levels of TNFa and IL-6 gene expression in peritoneal cells, spleen and lung after LPS injection is reduced in VIP KO vs.
WT mice. Female WT (C57BL6) (n=6) and VIP KO mice (n=6) were injected i.p. with LPS (40 mg/Kg), and cells or tissues were collected 0 and
2 hours post-injection and stored at 280uC until further analysis. RNA was extracted with the Trizol method, and the mRNA expressions of TNFa and
IL-6 were assessed by Real time RT-PCR. The mean values 6 SEM are shown (n=6/group). Student’s t-test *p,0.05.
doi:10.1371/journal.pone.0036922.g003
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were collected from WT (n=3) and VIP KO mice (n=3), and cultured in complete RPMI in triplicate in the presence or absence of LPS (10 ng/ml).
Supernatants were collected 2 (A) and 16 h (B) later, and stored at 220uC for analysis of TNFa and IL-6 levels by ELISA. Student’s t-test *p,0.05;
**p,0.01; ***p,0.001. Representative data are shown of four independent experiments.
doi:10.1371/journal.pone.0036922.g004
Figure 5. LPS-induced activation of the NF-kB pathway is diminished in VIP KO mice. Activation of the NF-kB signaling pathway was at
several time point determined by measurement of p-IkB protein levels by Western blot in (A, B) peritoneal cells isolated from WT and VIP KO mice
without or 1 hour after injection of LPS (40 mg/Kg), and (C, D) peritoneal cells isolated from WT and VIP KO mice and stimulated in culture with or
without LPS (10 ng/ml). Bar graphs represent the quantification of band density. Student’s t-test *p,0.05, ns=not significant. A representative blot
of three experiments is shown.
doi:10.1371/journal.pone.0036922.g005
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reduction suggests that the intrinsic ability of myeloid cells to elicit
an inflammatory response when exposed to LPS may be impaired
in the chronic absence of VIP.
Could a myeloid deficit in VIP KO mice contribute to their
EAE resistance? The proinflammatory activities of autoreactive
lymphocytes with Th1 and Th17 profiles have been shown to be
essential for EAE development [36]. However, myeloid cells have
been proposed as the ultimate effector cells that lead to the CNS
damage [31]. Myeloid cells may contribute to the pathogenesis of
EAE by secreting proinflammatory cytokines and chemokines, but
they may also mediate tissue damage in this model by releasing
enzymes that contribute to myelin destruction. For example, it has
been shown that metalloproteases, such as MMP-2, released by
macrophages cells in the CNS during EAE, enable the breakdown
of the blood brain barrier and the infiltration of the CNS
parenchyma by immune cells [37]. In addition to the resident
microglia, abundant numbers of macrophages infiltrate the CNS
during EAE. Depletion of macrophages with liposomal dichlor-
omethylene diphosphonate (Cl2MDP) after EAE induction but
before the appearance of clinical symptoms, led to the suppression
of full EAE development [38]. Because this treatment eliminates
bone marrow-derived macrophages leaving other populations such
as microglia intact [39], the results highlight a crucial role for
newly recruited macrophages for the development of the disease.
Supporting the relevance of the proinflammatory role of
macrophages in EAE, mice deficient in the macrophage
chemokine CCL-1 (MCP-1) [40] and its receptor CCR-2 [41]
are resistant to EAE, and genetic activation of the NF-kB pathway
specifically in myeloid cells led to a more severe course of the
disease [42]. We have found an impairment of NF-kB pathway
signaling in VIP KO mice peritoneal cells, indicating an intrinsic
defect in the response of these cells to at least some types of
inflammatory stimuli. Several innate immune receptors activate
the NF-kB pathway, including members of the IL-1R/TLR and
TNF-R1 superfamilies. In addition, LPS directly activates NF-kB
signaling through TLR4, which in turn triggers the expression of
proinflammatory cytokines such as TNFa, IL-6 and IL-12.
Although the specific mechanisms by which the NF-kB activation
is impaired in VIP KO mice remain to be elucidated, this could be
potentially due to abnormalities in TLR4 signaling in mice due to
chronic absence of VIP.
At this point, we can only hypothesize why the lack of VIP
results in decreased inflammation in the models of EAE and LPS-
induced endotoxemia. At first glance, the data in this report
contradicts the multiple existing studies demonstrating that VIP
inhibits the release of proinflammatory mediators by murine
macrophages [18,21,43,44]. In these studies, VIP was added
simultaneously or after the inflammatory stimulus. However, a few
studies have shown that VIP can stimulate various aspects of the
immune response under certain circumstances, for example when
added to resting cells in culture. In this regard, VIP promoted the
secretion of IL-6 by resting peritoneal macrophages in vitro,
whereas it inhibited the production of this cytokine in the presence
of LPS, suggesting that this peptide may exhibit dual actions
depending on the activation status of the cell [45,46]. In other
organs, such as the anterior pituitary and bone marrow, VIP also
stimulates IL-6 production, which in turn stimulates the release of
pituitary hormones and the growth and differentiation of
hematopoietic cells in the bone marrow [47]. Interestingly, Yadav
et al have recently shown that VPAC1 KO mice present milder
DSS-induced colitis compared to WT mice, suggesting that VIP
may exert proinflammatory actions through this receptor [30].
Although these results suggest an impaired functionality of VIP
KO of VPAC1 KO immune cells, other possibilities such as
compensation by other factors such as peptides/hormones or their
receptors may occur in mice when these molecules are chronically
absent, and cannot be ruled out at this point. For example, we
found a late increase in the systemic levels of IL-10 which could
potentially contribute to the increased survival in the KO mice,
although the importance of this mild induction needs to be further
studied. Finally, an interesting finding was that despite the reduced
mortality in VIP KO mice injected with LPS, we found a mild
lung histological inflammation and higher levels of TNFa mRNA
in this tissue in VIP KO mice in basal conditions. Szema et al
previously reported similar results in VIP KO males, and agrees
with the purported antiinflammatory actions of VIP [24]. It has
been shown that prolonged administration of a low dose of LPS
causes mild-degree inflammation which results in later poor
responsiveness to LPS, a phenomenon known as ‘‘endotoxin
tolerance’’ [48]. In would be interesting to determine if a
continuous basal inflammation in VIP KO mice may be related
to their decreased response to LPS. In conclusion, the unexpected
decreased response of female VIP KO mice to LPS highlights the
complexity of the actions of this peptide. This will need to be taken
into account when therapies are designed to target this signaling
pathway in inflammatory diseases.
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